Debunking the notion that boosters don't reduce Omicron symptomatic infections. Another new study from Qatar shows they are halved medrxiv.org/content/10.110… matched >400,000 people with mRNA vaccines 2 vs 3-dose
Booster vaccine effectiveness vs Omicron infections 62% (2 dose 32%) @UKHSA in people without Prior Covid assets.publishing.service.gov.uk/government/upl…
and higher with Prior Covid, hybrid immunity, as seen in all studies
Since the booster protection vs Delta symptomatic infections was 95% and vs Omicron it is ~50%, that is a 10-fold increase in breakthroughs
Which is why there is the misperception that there is no booster protection from infections or transmission w/ Omicron
*when there is*
They are cut in half; 90% vs hospitalizations
I watched @billmaher and @bariweiss last night @RealTimers and it is so obvious they are not in touch with the data and, unfortunately, propagating misinformation
Adding this important study, the largest household (~12,000) contact study for Omicron and Delta infections and *impact of booster* (3rd) dose vaccination:
Infections were reduced OR 0.54, CI 0.40-0.71)
Transmission risk reduced OR: 0.72, CI: 0.56-0.92) medrxiv.org/content/10.110…
First post of this thread, Figure label correction by authors (Moderna, panel B, not Pfizer in both panels)
And full discussion of these findings erictopol.substack.com/p/where-do-we-…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
We've known about KP.3's marked growth advantage since April and could have made the call then to make the new booster. That would have been aligned well with the current wave (available in July) 2/5 erictopol.substack.com/p/are-we-flirt…
But the FDA has tried to force fit Covid into an annual shot like flu, even though all data tells us it doesn't follow an annual pattern. Even the CDC acknowledges this now
3/5cdc.gov/ncird/whats-ne…
New CDC genomic data shows continued rise of the KP.3 variant that accounts for 1 of 3 Covid cases.
LB.1 is gaining, too, as JN.1 fades away
This variant growth advantage plot by @BenjMurrell (H/T @siamosolocani) shows why this is the case. Note KP.3 is the one at far left w/ almost 3-fold advantage to JN.1.
Reinforces why the decision to develop the KP.2 vaccine booster (instead of JN.1) was a good one
Spike mutation map to show the differences betweem KP.3 and JN.1 (and LB.1, KP.2)
The connection between #SARSCoV2 and neurodegeneration
@TheLancetNeuro
Quotes below: 1. SARS-CoV-2 infection should be considered as a risk factor for Alzheimer’s disease, even though the distinction between causation versus disease acceleration is not clear.thelancet.com/journals/laneu…
2. Inflammation in patients with COVID-19, and controlled experiments show prolonged neuro-inflammation after mild SARS-CoV-2 infection
in macaques.
3. A direct correlation has been reported
between prior SARS-CoV-2 infection and increased risk
of Alzheimer’s disease (figure).
4. So far, the estimated lifetime cumulative risk of dementia due to hospitalisation for any viral infection is 1·48 (95% CI 1·15–1·91).
Breaking down the risks and benefit for lecanemab, the amyloid beta-directed antibody vs Alzheimer's drug approved @US_FDA last year. It doesn't look good.
My oped on the JN.1 variant and the 2nd biggest US wave of infections (after Omicron) since the pandemic began
@latimes @latimesopinion #LongCovid latimes.com/opinion/story/…
Recent @CDCgov #SARSCoV2 wastewater data for current wave (vs Omicron Jan 2022 and subsequent waves), graph by @luckytran
Sorry, @washingtonpost, but this is not "another Covid-19 uptick" as you put it in your Health Alert. You ignore the best metric for infections that we have at present—wastewater—focusing only on hospitalizations washingtonpost.com/health/2024/01…